Itraconazole
- Generic Name
- Itraconazole
- Brand Names
- Sporanox, Tolsura
- Drug Type
- Small Molecule
- Chemical Formula
- C35H38Cl2N8O4
- CAS Number
- 84625-61-6
- Unique Ingredient Identifier
- 304NUG5GF4
- Background
One of the triazole antifungal agents that inhibits cytochrome P-450-dependent enzymes resulting in impairment of ergosterol synthesis. It has been used against histoplasmosis, blastomycosis, cryptococcal meningitis & aspergillosis.
- Indication
For the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: pulmonary and extrapulmonary blastomycosis, histoplasmosis, aspergillosis, and onychomycosis.
- Associated Conditions
- Aspergillosis, Blastomycosis, Chromoblastomycosis, Coccidioidal meningitis, Esophageal Candidiasis, Fungal Infections, Fungal skin infection, Histoplasmosis, Onychomycosis, Oropharyngeal Candidiasis, Paracoccidioidomycosis, Penicillium marneffei infection, Pulmonary coccidioides, Sporotrichosis, Vulvovaginal Candidiasis, Disseminated Other specified protozoal diseases
- Associated Therapies
- -
AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2016-02-05
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 142
- Registration Number
- NCT02675452
- Locations
- 🇨🇦
University Health Network-Princess Margaret Cancer Centre, Toronto, Ontario, Canada
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇩🇪Universitaetsklinikum Wuerzburg, Wuerzburg, Germany
A Phase I Study to Assess PK of AZD7986 Alone & With Verapamil, Itraconazole or Diltiazem in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2016-01-12
- Last Posted Date
- 2018-02-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 15
- Registration Number
- NCT02653872
- Locations
- 🇬🇧
Research Site, London, United Kingdom
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Risdiplam (RO7034067) Given by Mouth in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2015-12-17
- Last Posted Date
- 2018-10-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 33
- Registration Number
- NCT02633709
- Locations
- 🇳🇱
Pra International Group B.V, Groningen, Netherlands
Steady-State Comparative Bioavailability Study in Prophylaxis Patients of Lozanoc® 50 mg With Sporanox® 100 mg
- First Posted Date
- 2015-12-04
- Last Posted Date
- 2018-10-26
- Lead Sponsor
- Mayne Pharma International Pty Ltd
- Target Recruit Count
- 40
- Registration Number
- NCT02621905
- Locations
- 🇦🇺
St Vincent's Hospital, Darlinghurst, New South Wales, Australia
A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State
- Conditions
- Interventions
- First Posted Date
- 2015-11-18
- Last Posted Date
- 2020-02-12
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT02608034
- Locations
- 🇮🇱
Hadassah Ein Karem Hospital; Oncology Dept, Jerusalem, Israel
🇰🇷Samsung Medical Center; Gastroenterology, Seoul, Korea, Republic of
🇷🇺FSBSI "N. N. Blokhin Russian Cancer Research Center", Moscow, Russian Federation
Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic Study of GSK2881078 and Study to Evaluate the Effect of CYP3A4 Inhibition on PK of GSK2881078
- First Posted Date
- 2015-10-05
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 108
- Registration Number
- NCT02567773
- Locations
- 🇺🇸
GSK Investigational Site, Overland Park, Kansas, United States
Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of BI 1026706 in Healthy Male Subjects
- First Posted Date
- 2015-07-31
- Last Posted Date
- 2019-03-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 16
- Registration Number
- NCT02513446
- Locations
- 🇩🇪
1320.20.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
An Open-label, Two-period, Fixed-sequence Study to Evaluate Multiple-dose Itraconazole Effect on The Single-dose PK of PF-06372865 in Healthy Subjects
- First Posted Date
- 2015-06-19
- Last Posted Date
- 2017-06-26
- Lead Sponsor
- Pfizer
- Registration Number
- NCT02475746
- Locations
- 🇺🇸
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States
🇺🇸CRU New Haven, New Haven, Connecticut, United States
A Study to Investigate the Effect of CYP3A Inhibition on the Pharmacokinetics of RG1662 in Healthy Subjects
- First Posted Date
- 2015-06-12
- Last Posted Date
- 2016-08-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 12
- Registration Number
- NCT02470832
Study to Investigate Effects of Repeated Administration of Itraconazole on Pharmacokinetics of JNJ-42847922 in Healthy Male Participants
- First Posted Date
- 2015-05-28
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- Janssen Cilag N.V./S.A.
- Target Recruit Count
- 16
- Registration Number
- NCT02455856
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.